The Latest Breaking News from Flagship

Lord Darzi’s undeclared interests in four companies included $500,000 of shares in US-based healthcare venture

Disney+ has expanded its sports content by integrating ESPN, offering bundled and standalone subscribers access to live events and ESPN+ programming, while setting the stage for ESPN's direct-to-consumer Flagship service launch in 2025.

The pharma industry is poised to witness long-term growth with the introduction of generic medicines and growing demand for personalized and targeted treatments. Hence, fundamentally strong pharma stock AbbVie (ABBV) might be worth buying. However, it might not be the right time to invest in Pfizer (PFE). Keep reading.

Due to the emergence of new technologies and the introduction of generic medicines, the pharma industry seems well-positioned to witness growth. While pharma stocks should benefit from the industry tailwinds, let us analyze whether AbbVie (ABBV) is a better buy than Pfizer (PFE).

"What we are doing now, I don’t think anyone has done so far," Pfizer CEO Albert Bourla says.

Longines is offered three versions, all with a moon phase complication on the dial

Two weeks ago, ESPN Chairman Jimmy Pitaro said ESPN would become a standalone streaming destination 'when it makes sense.' After several reports of epic Q1 cord-cutting, that time might just have arrived

How Capcom's first field trip into the world of Zelda left a lasting influence on the series that can be felt today

Biogen and Seagen tapped new CEOs on Thursday but the biotech stocks diverged following the long-anticipated announcements.